TIL
NASDAQInstil Bio Inc.
Price$8.21-0.23 (-2.78%)
2026-03-042026-06-05
News · 26 weeks15-100%
2025-12-142026-06-07
Mix1090d
- SEC Filings8(80%)
- Other2(20%)
Latest news
25 items- SECSEC Form 10-Q filed by Instil Bio Inc.10-Q - Instil Bio, Inc. (0001789769) (Filer)
- SECInstil Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Instil Bio, Inc. (0001789769) (Filer)
- PRInstil Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateDALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial results and provided a corporate update. Recent Highlights Instil is evaluating potential acquisitions and in-licensing that may provide access to promising novel therapeutic candidatesCash position of approximately $74.7 million as of March 31, 2026 expected to fund current operating plan beyond 2027 "We continue to make progress refining Instil's strategy and positioning the company for its next phase of growth," said Bronson Crouch, Chief Executive Officer, Instil Bio. "
- SECSEC Form DEFA14A filed by Instil Bio Inc.DEFA14A - Instil Bio, Inc. (0001789769) (Filer)
- SECSEC Form DEF 14A filed by Instil Bio Inc.DEF 14A - Instil Bio, Inc. (0001789769) (Filer)
- SECInstil Bio Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Instil Bio, Inc. (0001789769) (Filer)
- SECSEC Form S-8 filed by Instil Bio Inc.S-8 - Instil Bio, Inc. (0001789769) (Filer)
- SECSEC Form 10-K filed by Instil Bio Inc.10-K - Instil Bio, Inc. (0001789769) (Filer)
- SECInstil Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Instil Bio, Inc. (0001789769) (Filer)
- PRInstil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateCompany evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development Cash position of $76.3 million as of December 31, 2025 expected to fund current operating plan beyond 2027 DALLAS, March 27, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its fourth quarter and full year 2025 financial results and provided a corporate update. Recent Highlights: In January 2026, Axion Bio, Inc., a wholly owned subsidiary of Instil, discontinued clinical development of AXN-2510 and entered into a termination agreement with ImmuneOnco B
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Instil Bio Inc.SCHEDULE 13G/A - Instil Bio, Inc. (0001789769) (Subject)
- ANALYSTInstil Bio downgraded by H.C. WainwrightH.C. Wainwright downgraded Instil Bio from Buy to Neutral
- SECInstil Bio Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - Instil Bio, Inc. (0001789769) (Filer)
- ANALYSTInstil Bio downgraded by Robert W. Baird with a new price targetRobert W. Baird downgraded Instil Bio from Outperform to Neutral and set a new price target of $7.00
- PRInstil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOncoDALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (NASDAQ:TIL) ("Instil") today announced that Axion Bio, Inc. ("Axion"), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) ("ImmuneOnco") have entered into an agreement terminating their license and collaboration agreement for AXN-2510 and AXN-27M ("Termination Agreement"). Under the terms of the Termination Agreement, all rights previously licensed to Axion, including global development and commercial rights outside Greater China, have reverted to ImmuneOnco, subject to a limited license to Axion to wind
- SECSEC Form 10-Q filed by Instil Bio Inc.10-Q - Instil Bio, Inc. (0001789769) (Filer)
- SECInstil Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Instil Bio, Inc. (0001789769) (Filer)
- PRInstil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateDALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its third quarter 2025 financial results and provided a corporate update. Recent Highlights: In September, ImmuneOnco, Instil's collaborator, presented updated data from additional patients with relapsed/refractory squamous non-small cell lung cancer treated with ‘2510 as monotherapy in a poster presentation at the 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.In October, Axion Bio, Instil's subsidiary, dosed the first patient in its Pha
- INSIDERCFO and CBO Laumas Sandeep sold $701,667 worth of shares (30,000 units at $23.39) and exercised 30,000 shares at a strike of $12.07 (SEC Form 4)4 - Instil Bio, Inc. (0001789769) (Issuer)
- SECSEC Form 144 filed by Instil Bio Inc.144 - Instil Bio, Inc. (0001789769) (Subject)
- PRInstil Bio Announces ImmuneOnco's Presentation of '2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC for PD-(L)1xVEGF bispecifics DALLAS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced that ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK) ("ImmuneOnco") presented preliminary efficacy and safety data of ‘2510 (IMM2510/AXN-2510) as monotherapy in a Phase 1 study of patients in China with previously treated squamous non-small cell lung
- SECSEC Form 10-Q filed by Instil Bio Inc.10-Q - Instil Bio, Inc. (0001789769) (Filer)
- SECInstil Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Instil Bio, Inc. (0001789769) (Filer)
- PRInstil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateWith the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 ("‘2510") anticipated before the end of 2025 Updated ‘2510 monotherapy data in squamous-NSCLC to be presented at IASLC's 2025 World Conference on Lung Cancer (WCLC) by ImmuneOnco DALLAS, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2025 financial results and provided a corporate update. Recent Highlights: In June, announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical OfficerIn July, announced the Investigational Ne
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Instil Bio Inc.SCHEDULE 13G/A - Instil Bio, Inc. (0001789769) (Subject)
TIL FAQ
7 questionsWhat does Instil Bio Inc. do?
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.Where does TIL stock trade?
Instil Bio Inc. (TIL) is listed on NASDAQ.What sector and industry is TIL in?
Instil Bio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Instil Bio Inc. go public?
Instil Bio Inc. (TIL) completed its IPO in 2021.What are analysts saying about TIL?
Instil Bio Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral on 2026-01-07. Recent price targets range from $600.00 to $1100.00.What companies are similar to TIL?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare TIL side-by-side with any of them on Quantisnow.How can I track TIL on Quantisnow?
Quantisnow aggregates Instil Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TIL to receive live email and push alerts on every new disclosure.